Carrick Therapeutics

Carrick Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of CDK7 and CDK12/13 inhibitors to treat aggressive and resistant forms of cancer. Its lead programs focus on combination therapies for advanced breast, prostate, and ovarian cancers, as well as potential applications in pancreatic cancer and Ewing's sarcoma. The company utilizes biomarker-driven patient selection to improve outcomes for patients with hormone receptor positive, HER2 negative advanced breast cancer.